A Seattle biotech startup born from a Nobel laureate’s lab has landed $12.7 million and partnerships with pharmaceutical giants Pfizer and Kite Pharma by using AI to design proteins that mount a multi-pronged attack on diseases. Read More
After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is… Read More
— Seattle-based Lighter Capital announced Patricia Elliott as chief sales officer and Kevin Fink as chief technology officer. The “alternative… Read More
Vancouver, B.C.-based Aquinox Pharmaceuticals is set to buy Neoleukin Therapeutics, a Seattle startup that launched out of the University of… Read More
Don't miss a headline!
Sign up for GeekWire's newsletters today.
Thanks for subscribing!
Check your inbox to confirm your subscription.
